

CURRICULUM VITAE

Tracey Lynn McLaughlin, M.D., M.S., M.S.

Stanford University School of Medicine
Division of Endocrinology, Gerontology, and Metabolism
300 Pasteur Drive, Rm. S-025
Stanford, CA 94305-5103
(650) 723-3186 • pager (650) 723-8222 x14850
tmclaugh@stanford.edu

Academic history:

Colleges and universities attended, degrees received

- 1988 B.A. Stanford University (Human Biology, distinction and honors)
- 1992 M.S. University of California, Berkeley, Joint Medical Program (Health and Medical Sciences: master's studies conducted at the School of Public Health)
- 1994 M.D. University of California, San Francisco, School of Medicine

Scholarships and honors

- 1984 Clark Scholar, Dallas, TX (molecular biology summer internship)
- 1992 The Secretary's Award for Innovations in Health and Human Services (for design of the Perinatal Health Corps)

Post-doctoral and residency training

- 1994-1997 Santa Clara Valley Medical Center, Internal Medicine Primary Care Program (Internship and Residency)
- 1997-2000 Stanford University Medical Center, Division of Endocrinology (Fellowship)
- 2002-2004 M.S., Stanford University, Epidemiology, Clinical Investigator Track, Division of Health Research and Policy

Board eligibility or boards passed

- 1994 National Board of Medical Examiners, parts I and II
- 1995 Medical Board of California
- 1997 American Board of Internal Medicine, Internal Medicine
- 1999/2010 American Board of Internal Medicine, Endocrinology
- 1995 Drug Enforcement Agency, USA

Employment history

Academic:

10/1/12-	Associate Professor Division of Endocrinology Stanford University School of Medicine
10/01/05 – 9/30/12	Assistant Professor Division of Endocrinology Stanford University School of Medicine
09/01/03-08/31/05	Instructor Division of Endocrinology Stanford University School of Medicine
04/01/02-07/31/05	Senior Research Scientist - Clinical Life Division of Endocrinology Stanford University School of Medicine
04/01/02-08/31/03	Clinical Instructor/Staff Physician Division of Endocrinology Stanford University School of Medicine
08/01/00-06/30/05	Clinical Life Science Research Associate Division of Endocrinology Stanford University School of Medicine

Non-Academic:

07/01/88-06/30/89	Research Associate Molecular Biology and Immunology Cetus Corporation, Emeryville
11/01/97-04/30/99	Pool Physician Kaiser Permanente, Redwood City
11/15/99-03/31/00	Attending Physician Internal Medicine and Endocrinology San Mateo County General Hospital

Public and professional service

Volunteer Professional Service:

1987	Amigos de las Americas (health improvement and education in Guanajuato, Mexico)
1989-1992	The Perinatal Health Corps, founder and director (University of California, Berkeley)

1989-1992 Resource Development Associates/Alameda County Dept of Public Health, intern (worked on the Healthy Start (Healthy People 2000) grant application for Oakland, CA)

Committees:

1988-present Stanford Alumni Association
1994-1997 UCSF Alumni Association
2002-2012 GCRC Advisory Committee, Stanford University Medical Center
2003-2012 Founder and Co-Chair, Diabetes Task Force, Stanford Hospital
2004 American Heart Association, Western Review Consortium
2005 Scientific Review Panel, SCCOR, NHLBI, NIH
2006-2012 Co-Chair, Bay Area Diabetes Club, San Francisco Bay Area
2007-present Steering Committee Member, World Congress on Insulin Resistance
2009-2012 Special Programs Committee, Endocrine Society
2010 Scientific Review Panel, Metabolic Dysfunction Collaborative, NIDDK, NIH
2011-2012 TRAM (Translational Research Program Committee), Stanford University
2012-2014 Steering Committee, American Diabetes Association
2013-present Women Sex Differences in Medicine Committee, Stanford University
2013,2017 Abstract Reviewer, American Diabetes Association
2014 Scientific Review Panel, CIDO, NIH/NIDDK
2015 Grant Reviewer, American Diabetes Association
2016-present Inpatient Diabetes Committee (extension of Diabetes Task Force)
2017 Scientific Review Panel, U01 GRADE study, NIH/NIDDK

Reviewer (Referee) for:

2002-present American Journal of Medicine
2002-present Journal of Clinical Endocrinology and Metabolism
2002-present Diabetes Care
2002-present Endocrine Practice
2005-present American Journal of Cardiology
2005-present Obesity Research
2005-present American Journal of Clinical Nutrition
2010-present Diabetes
2010-present Lancet

Professional Associations:

1995-1997 Member, American College of Physicians
1997-present Member, American Diabetes Association
1997-present Member, Endocrine Society
2002-2006 Member, American Association of Clinical Endocrinologists
2004-2006 Member, American Heart Association

Teaching Activities:

1. 2006- present: Human Pathology, Stanford Medical School (Neil Gesundheit): case discussions
2. 2007- present: Human Physiology, Stanford Medical School (Neil Gesundheit): "Type 2 Diabetes", "Obesity"
3. 2006- present: Introduction to Medicine (Peter Rudd): Clinician Mentor
4. 2008- present: Stanford Immersion in Medicine (undergraduates): Clinician Mentor
5. 2007- present: Practice of Medicine (Peter Pompei): "Diabetes and Nutrition"
6. 2004- present: Immunology 230: Introduction to Medicine (Charles Prober): Clinician Mentor
7. 2010: Human Biology core lecture, Stanford University: "Health Consequences of Obesity" (David Lyons): course director
8. 2011: Human Biology core lecture, Stanford University: "Obesity and Insulin Resistance: From Bedside to Bench." (David Lyons, course director)
9. 2011: Cardiovascular Medicine-Diabetes Journal Club MED223 (John Cooke). Mentor to fellow in journal article review and presentation.
10. 2008-present: Endocrinology Fellows Teaching Conferences. Type 2 Diabetes Outpatient, Inpatient Management of Diabetes, PCOS, Cystic-Fibrosis-Related Diabetes
11. Stanford Housestaff noon conferences 2008-present: Inpatient Diabetes

Post-degree honors and awards, including memberships in professional associations and learned societies

Honors and awards:

- | | |
|------|--|
| 1995 | Intern of the Year, Santa Clara Valley Medical Center |
| 1997 | Associates Research Poster Contest, winner, American College of Physicians |
| 2004 | American Federation for Medical Research, Junior Physician Investigator Award |
| 2005 | Northwestern University Feinberg School of Medicine Cardiovascular Young Investigators' Forum: Finalist |
| 2007 | Invited to join the Steering Committee for the World Congress on Insulin Resistance |
| 2008 | Expert Discussant in Symposium: "Hyperinsulinemic Hypoglycemia Following Gastric Bypass: Pathogenesis and Treatment", Joslin Diabetes Center |
| 2009 | Mentor to Recipient of Endocrine Fellows Foundation Award |
| 2012 | Mentor to Recipient of Stanford Translational Research and Applied Medicine Seed Grant |
| 2013 | Mentor to Recipient of TL2 Career Development Award |
| 2015 | Mentor to Recipient of Stanford Translational Research and Applied Medicine Seed Grant |

Ongoing Research Support

NIH/NIDDK R01 DK110186-01A1 McLaughlin (PI) 4/1/2017-3/30/2022

Longitudinal multi-omic profiles to reveal mechanisms of obesity-mediated insulin resistance

The goal of this research is to follow research participants over a weight gain perturbation to detect biomolecules that are associated with worsening insulin resistance. We will use a novel multi-omic platform that represents the most extensive molecular characterization available today.

Role (PI)

National Institutes of Health-Project 122525 Parsonnet (PI) 4/1/2017- 3/31/21

Longitudinal investigations of the virome of young children and its associations with obesity

Major Goals:

Role: Co-investigator

NIH/NIDDK 2 R01 DK081371-06 Palaniappan (PI) 9/1/2014 – 3/31/2019

Strength Training Regimen for Normal-weight Diabetics (STRONG-D)

This study seeks to determine whether strength training, aerobic training, or combined strength and aerobic training, is most effective, compared to no exercise, in treating normal-weight individuals with type 2 diabetes.

Role (Co-Investigator)

American Heart Association 17GRNT33460003 McLaughlin (PI) 1/1/2017 – 12/31/18

Adaptive Immune Response in Visceral and Subcutaneous Fat: Role in Human Insulin Resistance

The goal of this research is to establish whether there is a fundamental role for adaptive immunity, specifically T cells, in macrophage activation, systemic inflammation, and human insulin resistance

Role (PI)

Cardiometabolic Disease Research Foundation McLaughlin (PI) 9/1/16- 8/31/17

Human Epicardial Fat and Coronary Atherosclerosis Adjacent to the Myocardial Bridge

The goal of the research is to measure inflammation in epicardial fat in relation to geographic association with atherosclerotic plaque in humans with myocardial bridge.

Role (PI)

ADA Translational Research Award McLaughlin (PI) 1/1/14-12/31/17

Adaptive Immune Response: Role in Human Insulin Resistance

The goal of this research is to test the hypothesis that in human obesity, the balance of pro and anti-inflammatory T cells in adipose tissue is related to insulin sensitivity and macrophage phenotype, which will be measured in adipose tissue and peripheral blood before and after experimentally-induced weight gain.

Role (PI)

Stanford Cardiovascular Institute Seed Grant McLaughlin (PI) 9/1/16 – 8/31/17

Predicting Cardiovascular Benefits of Anti-diabetic Drugs Using Induced Pluripotent Stem Cell-derived Endothelial Cells

The objective of this proposal is to test the central hypothesis that iPSC-ECs derived from T2DM patients can be used to predict patient response to selected anti-diabetic medications.

Role (PI)

Stanford University Translational Medicine Seed Grant McLaughlin (PI) 1/1/14-12/31/16

A Proof of Concept Study of the Effect of the Glucagon-like Peptide-1 Receptor Antagonist Exendin (9'39) On Plasma Glucose Excursions in Subjects with Hyperinsulinemic Hypoglycemia Following RYGB Surgery

The goal of this research is to elucidate the role of GLP-1 in causing hypoglycemia in patients with symptomatic hyperinsulinemic hypoglycemia following RYGB, and to test efficacy of GLP-1 blockade
Role (PI)

NIH 1U54DE02378901 Snyder (PI) 9/06/13- 8/31/17

Longitudinal Multiomics Microbial Profiling in Healthy and Disease Individuals

The goal of this study is to profile prediabetic patients over time to identify biomarkers and microbiome profiles that predict conversion to type 2 diabetes.

Role (Co-Investigator)

Novo Nordisk, IIT McLaughlin (PI) 09/01/14 - 08/31/17

Effect of Liraglutide on Macrophage Polarization in Human Adipose Tissue and Peripheral Blood

The goal of this study is to determine whether liraglutide causes M2 polarization in human adipose tissue and blood in obese type 2 diabetics.

Role: PI

Completed Research Support

Endocrine Fellows Foundation McLaughlin (PI) 06/01/98- 06/01/00

Muscle Insulin Resistance – the “Not-so-Thrifty Genotype.

Role: PI

NIH/NIDDK , K23 (RR16071-01) McLaughlin (PI) 08/01/00-07/31/05

Obesity, Insulin Resistance and the Role of Weight Loss in Reducing Cardiovascular Risk.

Role: K23 with mentor Gerald Reaven

Takeda Pharmaceuticals Reaven (PI) 04/06/05 – 04/05/07

Role of Adipocytes in Insulin Resistance and Cardiovascular Disease Risk: Modulation With Pioglitazone

Determine the role of the adipocyte in the development of insulin resistance and cardiovascular disease. Obese, insulin-resistant versus -sensitive individuals underwent measures of adipocyte structure, function, and gene expression before and after treatment with pioglitazone.

Role: Co-PI

Clinical Research Feasibility Funds Award McLaughlin (PI) 06/01/05 – 05/31/07

Role of Adipocytes in Insulin Resistance and Cardiovascular Disease Risk: Modulation With Pioglitazone

Supplemental funding to the above award that is specifically designated for the cross-sectional comparison of fat distribution in insulin-resistant versus insulin-sensitive individuals who are equally obese.

Role: PI

NIH/NIDDK 5 R01DK071309 Reaven (PI) 05/01/05-04/30/09

Integrating the Metabolic and Genetic Faces of Obesity

Explore the hypothesis that impaired adipocyte differentiation and subcutaneous fat storage plays a role in insulin resistance. Insulin resistant and insulin sensitive obese subjects were randomized to pioglitazone or weight loss. Metabolic testing and adipose tissue biopsies were done before and after intervention.

Inventions and Patents

Stanford Docket S12-372: this invention was licensed to Eiger Biopharmaceuticals 5/4/2015

Provisional Patent USTPO filed 11/16/15

Provisional Patent PCT filed 6/10/16 (application numbers 62254175, 62329850)

Publications

Peer-reviewed articles (72 published, 2 under review, and 8 invited review articles)

1. **Sumits (McLaughlin) T.** The Perinatal Health Corps. *Pub Health Rep* 1992; 107:219-220.
2. **Sumits (McLaughlin) T,** Bennett R, Gould J. Maternal risks for very low birth weight infant mortality. *Pediatrics* 1996; 98:236-241.
3. Abbasi F; **McLaughlin T**; Lamendola C; Lipinska I; Tofler G; Reaven GM. Comparison of plasminogen activator inhibitor-1 concentration in insulin-resistant versus insulin-sensitive healthy women. *Arter, Thromb, and Vasc Biol* 1999; 19(11):2818-2821.
MY ROLE: I recruited subjects and performed metabolic tests.
4. Abbasi F; **McLaughlin T**; Lamendola C; Yeni-Komshian H; Tanaka A; Wang T; Nakajima K; Reaven GM. Fasting remnant lipoprotein cholesterol and triglyceride concentrations are elevated in nondiabetic, insulin-resistant, female volunteers. *J Clin Endocrinol Metab* 1999; 84(11):3903-3906.
MY ROLE: I recruited subjects and performed metabolic tests and collated data.
5. Chen NG; Abbasi F; Lamendola C; **McLaughlin T**; Cooke JP; Tsao PS; Reaven GM. Mononuclear cell adherence to cultured endothelium is enhanced by hypertension and insulin resistance in healthy nondiabetic volunteers. *Circulation* 1999; 100(9):940-943.
MY ROLE: I recruited subjects and performed metabolic tests and collated data.
6. **McLaughlin T**; Abbasi F; Carantoni M; Schaaf P; Reaven G. Differences in insulin resistance do not predict weight loss in response to hypocaloric diets in healthy obese women. *J Clin Endocrinol Metab* 1999; 84(2):578-581.
7. Abbasi F; Carantoni M; **McLaughlin T**; Reaven GM. Plasma insulin concentration is more tightly linked to plasma leptin concentration than is the body mass index. *Metab: Clin and Experim* 2000; 49:544-547.
MY ROLE: I recruited subjects and performed metabolic tests and collated data.
8. **McLaughlin T**; Abbasi F; Lamendola C; Yeni-Komshian H; Reaven G. Carbohydrate-induced hypertriglyceridemia: an insight into the link between plasma insulin and triglyceride concentrations. *J Clin Endocrinol Metab* 2000; 85(9):3085-3088.
9. Abbasi F; **McLaughlin T**; Lamendola C; Kim HS; Tanaka A; Wang T; Nakajima K; Reaven GM. High carbohydrate diets, triglyceride-rich lipoproteins, and coronary heart disease risk. *Am J Cardiol* 2000; 85:45-48.
MY ROLE: I recruited subjects and performed metabolic tests and collated data.

10. Abbasi F; **McLaughlin T**; Lamendola C; Reaven GM. The relationship between glucose disposal in response to physiological hyperinsulinemia and basal glucose and free fatty acid concentrations in healthy volunteers. *J Clin Endocrinol Metab* 2000; 85(3):1251-1254.
MY ROLE: I recruited subjects and performed metabolic tests and collated data.
11. Abbasi F; **McLaughlin T**; Lamendola C; Reaven GM. Insulin regulation of plasma free fatty acid concentrations is abnormal in healthy subjects with muscle insulin resistance. *Metab: Clin and Experim* 2000; 49(2):151-154.
MY ROLE: I recruited subjects and performed metabolic tests and collated data.
12. **McLaughlin T**; Abbasi F; Kim HS; Lamendola C; Schaaf P; Reaven G. Relationship between insulin resistance, weight loss and coronary heart disease risk in obese healthy women. *Metabolism* 2001; 50:795-800.
13. **McLaughlin T**; Abbasi F; Lamendola C; Kim H; Reaven GM. Metabolic changes following sibutramine-assisted weight loss in obese individuals: role of free fatty acids in the insulin resistance of obesity. *Metabolism* 2001; 50:819-824.
14. Kim HS; Abbasi F; Lamendola C; **McLaughlin T**; Reaven GM. Effect of insulin resistance on postprandial elevations of remnant lipoprotein concentrations in postmenopausal women. *Am J Clin Nutr.* 2001; 74:592-595.
MY ROLE: I recruited subjects and performed metabolic tests and collated data.
15. Abbasi F; Asagmi T; Cooke JP; Lamendola C; **McLaughlin T**; Reaven GM. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. *Am J Cardiol* 2001; 88:1201-1203.
MY ROLE: I recruited subjects and performed metabolic tests and collated data.
16. Cataldo NA; Abbasi F; **McLaughlin T**; Lamendola C; Reaven GM. Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone. *Fertil Steril* 2001; 76:1057-59.
MY ROLE: I recruited subjects and performed metabolic tests and collated data.
17. Stuhlinger MC, Abbasi F, Lamendola C, **McLaughlin T**, Cooke JP, Reaven GM, Tsao PS. Close relationship between insulin resistance and the endogenous nitric oxide synthase inhibitor, ADMA. *JAMA* 2002; 287:1420-1426.
MY ROLE: I recruited subjects and performed metabolic tests and collated data.
18. **McLaughlin T**; Abbasi F; Lamendola C; Leary E; Reaven GM. Comparison in patients with type 2 diabetes of fibric acid versus HMG-CoA reductase inhibitor treatment of combined dyslipidemia. *Metabolism* 2002; 51:1355-1359.
19. Asagami T, Abbasi F, Steulinger M, Lamendola C, **McLaughlin T**, Cooke JP, Reaven GM, Tsao PS. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. *Metabolism* 2002; 51:843-846.
MY ROLE: I recruited subjects and performed metabolic tests and collated data.
20. Abbasi F, Brown BW, Lamendola C, **McLaughlin T**, Reaven GM. Relationship between obesity, insulin resistance, and coronary heart disease risk. *J Am Coll Cardiol* 2002; 40:937-943.
MY ROLE: I recruited subjects and performed metabolic tests and collated data.

21. **McLaughlin T**, Abbasi F, Lamendola C, Liang L, Reaven G, Schaaf P, Reaven P. Differentiation between obesity and insulin resistance in the association with c-reactive protein. *Circulation* 2002; 106: 2908-2912.
22. Chu JW, Abbasi F, Kulkarni KR, Lamendola C, **McLaughlin T**, Scalisi JN, Reaven GM. Multiple lipoprotein abnormalities associated with insulin resistance in healthy volunteers are identified by the vertical auto profile-II methodology. *Clin Chem* 2003; 49(6 Pt 1):1014-1017.
MY ROLE: I recruited subjects and performed metabolic tests and collated data.
23. Tuan C, Abbasi F, Lamendola C, **McLaughlin T**, Reaven GM. The clinical utility of plasma glucose and insulin concentrations in identifying insulin resistant individuals. *Am J Cardiol* 2003; 92:606-610.
MY ROLE: I recruited subjects and performed metabolic tests and collated data.
24. **McLaughlin T**, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. *Ann of Intl Med* 2003; 139:802-809.
25. **McLaughlin T**, Allison G, Abbasi F, Lamendola C, Reaven G. Prevalence of insulin resistance and associated cardiovascular risk factors among normal, overweight, and obese individuals. *Metabolism* 2004; 53:495-499.
26. Abbasi F, Lamendola C, **McLaughlin T**, Hayden J, Reaven GM, Reaven PD. Plasma adiponectin concentrations do not increase in association with moderate weight loss in insulin-resistant, obese women. *Metabolism* 2004; 53:280-283.
MY ROLE: I recruited subjects and performed metabolic tests and collated data.
27. **McLaughlin T**, Lamendola C, Abbasi F, Cummings DE. Plasma ghrelin concentrations are suppressed in obese individuals who are insulin-resistant but not insulin-sensitive. *J Clin Endocrinol Metab* 2004; 89:1630-1635.
28. Chu JW, Abbasi F, **McLaughlin T**, Lamendola C, Schaaf P, Carlson TH, Leary ET, Reaven GM. Lipoprotein risk factors for cardiovascular disease in patients with type 2 diabetes mellitus treated with oral antihyperglycaemic agents. *Diabetes Obes Metab* 2003; 5:333-337.
MY ROLE: I recruited subjects and performed metabolic tests.
29. Cheal KL, Abbasi F, Lamendola C, **McLaughlin T**, Reaven GM, Ford ES. Relationship to insulin resistance of the Adult Treatment Panel III diagnostic criteria for identification of the metabolic syndrome. *Diabetes* 2004; 53:1195-1200.
MY ROLE: I recruited subjects and performed metabolic tests and collated data.
30. Abbasi F, Chu JW, Lamendola C, **McLaughlin T**, Hayden J, Reaven GM, Reaven PD. Discrimination between obesity and insulin resistance in the relationship with adiponectin. *Diabetes* 2004; 53:585-590.
MY ROLE: I recruited subjects and performed metabolic tests and collated data.

31. Abbasi F, Chu JW, **McLaughlin T**, Lamendola C, Leary ET, Reaven GM. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. *Metabolism* 2004; 53:159-164.
MY ROLE: I recruited subjects and performed metabolic tests and collated data.
32. Lamendola C, Abbasi F, Chu J, Hutchinson H, Cain V, Leary E, **McLaughlin T**, Stein E, Reaven G. Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin resistant, nondiabetic patients with combined dyslipidemia. *Am J Cardiol* 2005; 95:189-193.
MY ROLE: I recruited subjects and performed metabolic tests and collated data.
33. Kim S, Abbasi F, Chu JW, **McLaughlin T**, Lamendola C, Polonsky K, Reaven G. Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals. *Diabetes* 2005; 54:2447-52.
MY ROLE: I recruited subjects and performed metabolic tests and collated data.
34. **McLaughlin T**, Reaven G, Abbasi F, Lamendola C, Krauss R. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? *Am J Cardiol* 2005; 96:399-404.
35. Chu JW, Abbasi F, Lamendola C, **McLaughlin T**, Reaven GM. Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects. *Diabetes Vasc Dis Res* 2005; 2:37-41.
MY ROLE: I recruited subjects and performed metabolic tests.
36. **McLaughlin T**, Stuhlinger M, Lamendola C, Abbasi F, Reaven GM, Tsao PS. Plasma Asymmetric dimethylarginine concentrations are elevated in insulin-resistant women and fall with weight loss. *J Clin Endocrinol Metab* 2006; 91:1896-900.
37. Abbasi F, Chang SA, Chu JW, Ciaraldi TP, **McLaughlin T**, Reaven GM, Reaven PD. Improvements in insulin resistance with weight loss, in contrast to rosiglitazone, are not associated with changes in plasma adiponectin multimeric complexes. *AJP: Reg, Integr and Comp Physiol* 2006;290:R139-44.
MY ROLE: I recruited subjects and performed metabolic tests and collated data.
38. Cataldo N, Abbasi F, **McLaughlin T**, Basina M, Fechner PY, Giudice LC, Reaven GM. Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome. *Hum Reprod* 2006; 21:109-120.
MY ROLE: I recruited subjects and performed metabolic tests.
39. **McLaughlin T**, Carter S, Abbasi F, Lamendola C, Schaaf P, Yee G, Reaven G. Moderate variations in carbohydrate and fat content of hypocaloric diets: impact on weight loss, insulin resistance, and cardiovascular risk in insulin-resistant, obese individuals. *Am J Clin Nutr* 2006; 84:813-21.
40. Reaven G, **McLaughlin T**. Why the plasma triglyceride/high-density lipoprotein cholesterol concentration ratio does not predict insulin resistance in African Americans. *Archives of Internal Medicine* 2006;166:249-50.

41. Abbasi F, Farin HM, Lamendola C, **McLaughlin T**, Schwartz EA, Raven GM, Reaven PD. The relationship between plasma adiponectin concentration and insulin resistance is altered in smokers. *J Clin Endocrinol Metab* 2006;91:5002-07.

MY ROLE: I recruited subjects and performed metabolic tests and collated data.

42. Farin HM, Abbasi F, Kim SH, Lamendola C, **McLaughlin T**, Reaven GM. The relationship between insulin resistance and dyslipidaemia in cigarette smokers. *Diabetes Obes Metab.* 2007; 9:65-9.

MY ROLE: I recruited subjects and performed metabolic tests.

43. Beysen C, Murphy EJ, **McLaughlin T**, Riiff T, Lamendola C, Turner HC, Awada M, Turner SM, Reaven G, Hellerstein MK. Whole-Body Glycolysis Measured by the Deuterated-Glucose Disposal Test Correlates Highly with Insulin Resistance in vivo. *Diabetes Care.* 2007; 30:1143-9.

MY ROLE: I recruited subjects and performed metabolic tests.

44. **McLaughlin T**, Abbasi F, Lamendola C, Reaven G. Heterogeneity in prevalence of risk factors for cardiovascular disease and type 2 diabetes in obese individuals: impact of differences in insulin sensitivity. *Archives Int Med.* 2007; 167:642-8.

45. **McLaughlin T**, Sherman A, Tsao P, Gonzalez O, Yee G, Lamendola C, Reaven GM, Cushman SW. Enhanced proportion of small adipose cells in insulin-resistant versus insulin-sensitive individuals implicates impaired adipogenesis. *Diabetologia.* 2007; 50:1707-15.

46. Ryan, M, Abbasi F, Lamendola C, Carter S, **McLaughlin T**. Serum alanine aminotransferase levels decrease further with carbohydrate than fat restriction in insulin resistant adults. *Diabetes Care.* 2007; 30:1075-80.

47. **McLaughlin T**, Carter S, Abbasi F, Lamendola C, Schaaf P, Basina M, Reaven G. Clinical efficacy of two calorie-restricted diets in overweight patients with type2 diabetes not receiving pharmacological agents: comparison of moderate fat versus carbohydrate reductions. *Diabetes Care.* 2007;30:1877-9.

48. Palaniappan LP, Kwan AC, Abbasi F, Lamendola c, **McLaughlin TL**, Reaven GM. Lipoprotein abnormalities are associated with insulin resistance in South Asian Indian women. *Metabolism.* 2007; 56:899-904.

MY ROLE: I recruited subjects and performed metabolic tests and collated data.

49. **McLaughlin T**, Carter S, Schweitzer P, Chi-Gang Y, Lamendola C, Abbasi F, Reaven G. Persistence of weight loss and associated metabolic benefits in insulin resistant, obese individuals following a weight loss program of relatively short duration. *Diabetes, Obesity, and Metabolism,* 2008; 10:1186-94.

50. **McLaughlin T**, Deng A, Gonzales O, Aillaud M, Yee, G, Lamendola C, Abbasi F, Connolly A, Sherman A, Cushman C, Reaven GM, Tsao P. Comparison of Inflammatory Markers in Subcutaneous Adipose Tissue Obtained from Equally Obese Insulin Resistant and Insulin Sensitive Women. *Diabetologia,* 2008; 51:2303-8.

51. Abbasi F, Farin HM, Lamendola C, McGraw L, **McLaughlin T**, Reaven GM. Pioglitazone administration decreases cardiovascular disease risk factors in insulin-resistant smokers. *Metabolism*. 2008, 57:1108-14.
MY ROLE: I recruited subjects and performed metabolic tests and collated data.
52. Backes AC, Abbasi F, Lamendola C, **McLaughlin TL**, Reaven G, Palaniappan LP. Clinical experience with a relatively low carbohydrate, calorie-restricted diet improves insulin sensitivity and associated metabolic abnormalities in overweight, insulin resistant South Asian Indian women. *Asia Pac J Clin Nutr*. 2008;17:669-71.
MY ROLE: I assisted with design, recruited subjects, and performed metabolic tests.
53. Kim SH, Liu TC, Abbasi F, Lamendola C, Morton JM, Reaven GM. **McLaughlin TL**. Plasma Glucose and Insulin Regulation is Abnormal Following Gastric Bypass Surgery with or without Neuroglycopenia. *Obesity Surgery*. 2009, 19:1550-6.
54. Liu A*, **McLaughlin T***, Liu T, Sherman A, Yee G, Abbasi F, Lamendola C, Morton J, Cushman SW, Reaven GM, Tsao PS. Subcutaneous adipose tissue hypertrophy is associated with intra-abdominal adipose cell hyperplasia in insulin resistant individuals. *Obes Surg*. 2009, 19(11):1564- 73. ***Equal contributors**
55. **McLaughlin T**, Peck MC, Holst J, Deacon C. Reversible Hyperinsulinemic Hypoglycemia after Gastric Bypass: A Consequence of Altered Nutrient Delivery. *J Clin Endocrinol Metab*. 2010 95:1851-5.
56. **McLaughlin T**, Liu T, Yee G, Abbasi F, Lamendola C, Reaven G, Tsao P, Cushman SW, Sherman A. Pioglitazone Increases the Proportion of Small Cells in Human Subcutaneous Adipose Tissue. *Obesity* 2010, 18:926-31.
57. **McLaughlin T**, Deng A, Yee G, Lamendola C, Reaven G, Tsao P, Cushman S, Sherman A. Inflammation in Subcutaneous Adipose Tissue: Relationship to Adipose Cell Size. *Diabetologia* 2010, 53:369-77.
58. Kim SH, Abbasi F, Lamendola C, Reaven GM, **McLaughlin T**. Glucose-stimulated insulin secretion in gastric bypass patients with hypoglycemic syndrome: no evidence for inappropriate pancreatic beta-cell function. *Obes Surg* 2010, 20:1110-6.
59. Liu A, Sonmez A, Yee G, Bazuine M, Arroyo M, Sherman A, **McLaughlin T**, Reaven G, Cushman S, Tsao P. Differential adipogenic and inflammatory properties of small adipocytes in Zucker Obese and Lean rats. *Diab Vasc Dis Res*. 2010, 7:311-8.
MY ROLE: I contributed to hypothesis generation and data interpretation.
60. Winer DA, Winer S, Shen L, Wadia PP, Yantha J, Palster G, Tsui H, Wu P, Davidson MG, Alonso MN, Leong Sweixian, Glassford A, Caimoll M, Tedder TF, **McLaughlin T**, Miklos D, Dosch HM, Engleman EG. B Lymphocytes Promote Insulin Resistance through Modulation of T Lymphocytes and Production of Pathogenic IgG Antibody. In Press: *Nature Medicine* 2011.
MY ROLE: I provided the human samples for this study and participated in study design/writing of the human analyses portion.

61. **McLaughlin T**, Yee G, Glassford A, Lamendola C. Use of a Two-stage Insulin Suppression Test to Assess the Relationship Between Insulin-Suppression of Lipolysis and Insulin-Mediated Glucose Uptake in Overweight/Obese, Nondiabetic Women. *Metabolism* 2011, 60:1741-7.
62. **McLaughlin T**, Lamendola C, Liu A, Abbasi F. Subcutaneous and Visceral Fat Depots: Bidirectional Relationship with Insulin Resistance. *J Clin Endocrinol Metab* 2011, 96:E1756-60.
63. Panel V, Hugendubler L, Gavrilova O, Liu A, **McLaughlin T**, Kaestner KH, Mueller E. The winged helix transcription factor Foxa3 regulates adipocyte differentiation and depot-selective fat tissue expansion. *Mol Cell Biol*. 2013, 33(17):3392-9. PMC3753856
MY ROLE: I recruited and studied the human subjects
64. **McLaughlin T**. Metabolic Heterogeneity of Obesity: Role of Adipose Tissue. *Int J Obesity*, 2012, S8-10.
65. **McLaughlin T**, Lamendola C, Coghlan N, Liu TC, Lerner K, Sherman A, Cushman SW. Subcutaneous Adipose Cell Size and Distribution: Relationship to Insulin Resistance and Body Fat. *Obesity* 2014, 22:673.
66. **McLaughlin T**, Liu LF, Lamendola C, Morton J, Rivas H, Winer D, Tolentino L, Choi O, Shen L, Engleman E. T Cell Profile in Adipose Tissue is Associated with Insulin Resistance in Humans. *Arterioscler Thromb Vasc Biol* 2014, 34:2637-43.
67. The Integrative HMP Research Network Consortium. The Integrative Human Microbiome Project: Dynamic Analysis of Microbiome-Host Omics Profiles during Periods of Human Health and Disease. *Cell Host & Microbe* 2014, 16: 291-303
68. Liu, LF, Kodama K, Wei K, Butte AJ, **McLaughlin T**. The Receptor CD44 is Associated with Insulin Resistance in Caucasian Subjects. *Diabetologia* 2015; 58:1579-86. PMID: 25952479
69. Craig, C, **McLaughlin T**. The Use of Gastrostomy Tube for the Long-Term Remission of Hyperinsulinemic Hypoglycemia after Roux-en-Y Gastric Bypass - a Case Report. *Endocrine Practice* 2014.
70. Allister CA, Lamendola CA, Liu LF, Craig CM, Cushman SW, Hellerstein MK, **McLaughlin T**. In vivo 2H2O administration directly reveals impaired triglyceride storage in subcutaneous adipose tissue of insulin-resistant, but not of insulin-sensitive, moderately-obese humans. *J Lipid Research*. 2015 Feb;56(2):435-9
71. **McLaughlin T**, Craig C, Liu LF, Perelman D, Allister C, Spielman D, Cushman SW. Adipose Cell Size and Regional Fat Deposition as Predictors of Metabolic Response to Overfeeding in Insulin-Resistant and Insulin-Sensitive Humans. *Diabetes*. 2016 Feb 16. PMID: 26733356
72. Weaver K, Craig C, **McLaughlin T**. Pasireotide Induced Adrenal Insufficiency. *Clin Endocrinol (Oxf)*. 2016 [Epub ahead of print] PMID: 26733356
73. Perelman, D, Coghlan N, Lamendola C, Carter S, Abbasi F, **McLaughlin T**. Substituting Poly- and Mono-unsaturated Fat for Dietary Carbohydrate Reduces Hyperinsulinemia in Women with Polycystic Ovary Syndrome. *Gynecol Endocrinol*. 2017, 33(4):324-327.

74. Wong JC, Kreuger KC, Costa MJ, Aggarwal A, Du H, **McLaughlin TL**, Feldman BJ. A glucocorticoid- and diet-responsive pathway toggles adipocyte precursor cell activity in vivo. *Sci Signal*. 2016, 9(451):ra103.
MY ROLE: I conducted the clinical portion of the study and prepared human adipose tissue samples
75. Liu LF, Craig CM, Tolentino LL, Choi O, Cushman S, Engleman EG, **McLaughlin T**. Macrophage removal increases human preadipocyte differentiation in omental adipose tissue. *PLOS-1* 2017, 12(2):e0170728
76. Xiao Li,*, Jessilyn Dunn,*, Denis Salins,*, Gao Zhou, Wenyu Zhou, Sophia Miryam Schüssler-Fiorenza Rose, Dalia Perelman, Elizabeth Colbert, Ryan Runge, Shannon Rego, Ria Sonecha, Somalee Datta, **Tracey McLaughlin**, and Michael P. Snyder. Digital Health: Tracking Physiomes and Activity Using Wearable Sensors Reveals Useful Health-Related Information. *PLoS Biol*. 2017 Jan 12;15(1):e2001402.
MY ROLE: I oversaw the clinical portion of the study
77. Craig CM, Liu LF, Deacon CF, Holst JJ, **McLaughlin TL**. Critical role for GLP-1 in symptomatic post-bariatric hypoglycemia. *Diabetologia* 2017, 60(3):531-540.
78. Piening B, Zhou W, Contrepois K, Rost H, Gu G, Mishra T, Hansen B, Bautista E, Leopold S, Yeh C, Spakowicz D, Kukurba K, Perelman D, Craig C, Colbert E, Salins D, Rego S, Wheeler J, Abbott C, Pitteri S, Sodergren E, **McLaughlin T***, Weinstock G*, and Michael Snyder*. Integrative Personal Omics Profiles During Periods of Weight Gain and Loss. *Science* 2017, *Under Review*. *co-senior authors
79. Craig CM, Liu LF, Nguyen T, Price C, Colbert E, **McLaughlin T**. Metabolic, clinical, and pharmacokinetic responses to subcutaneous exendin (9-39) in patients with post-bariatric hypoglycemia. *Diabetes, Obesity, and Metabolism* 2017, *Under Review*.

Invited articles (8 total)

1. **McLaughlin T**; Reaven G. Insulin resistance and hypertension. Patients in double jeopardy for cardiovascular disease. *Geriatrics* 2000; 55(6):28-32, 35.
2. **McLaughlin T**; Camargo C. Insulin and obesity. *Mdvista e-journal* 2001; May.
3. **McLaughlin T**, Reaven GM. Beyond type 2 diabetes: the need for a clinically useful way to identify insulin resistance. *Am J Med* 2003; 114(6):501-502.
4. **McLaughlin T**. Obesity, insulin resistance, and cardiovascular disease: identifying the Individuals at highest risk. *Pract Diab* 2004; 23:6-11.
5. **McLaughlin T**. The Insulin Resistance (Dysmetabolic) Syndrome and obesity. *Endo Pract* 2003; 9(Suppl 2):58-62.
6. Reaven G, Abbasi F, **McLaughlin T**. Obesity, insulin resistance, and cardiovascular disease. *Recent Prog Horm Res* 2004; 59:207-223.
7. Ramsetty A, **McLaughlin T**. Cystic Fibrosis-Related Diabetes. *Pract Diab* 2005; 24:23-29.

8. **McLaughlin T**, Ackerman SE, Shen L, Engleman E. Role of innate and adaptive immunity in obesity-associated metabolic disease. *J Clin Invest* 2017, 127(1):5-13.

Abstracts (21 of 34+ selected)

1. Abbasi F, Chu JW, Lamendola C, **McLaughlin T**, Schaaf P, Reaven GM. Fasting plasma glucose concentrations correlate highly with postprandial glycemic responses in patients with type 2 diabetes mellitus. *Diabetes* 2002; 51(Suppl 2): PO-2449.
2. Abbasi F, Chu JW, Lamendola C, **McLaughlin T**, Schaaf P, Reaven G. Effect of metformin treatment on coronary heart disease risk factors and soluble adhesion molecules in patients with type 2 diabetes mellitus. *Diabetes* 2002; 51(Suppl 2): PO-2067.
3. **McLaughlin T**, Abbasi F, Lamendola C, Leary E, Reaven GM. Comparison in patients with type 2 diabetes of fibric acid versus HMG-CoA reductase inhibitor treatment of combined dyslipidemia. *Diabetes* 2002; 51(Suppl 2): PO-2036.
4. Chu JW, Abbasi F, Lamendola C, **McLaughlin TL**, Tsao PS, Reaven GM. Rosiglitazone enhances insulin sensitivity and decreases cardiovascular risk factors in insulin-resistant subjects without diabetes mellitus. *Diabetes* 2002; 51(Suppl 2): PO-553.
5. **McLaughlin T**, Reaven GM, Lamendola C, Abbasi F, Cummings D. Insulin regulates ghrelin concentrations in obese humans. (Abstract). *Diabetes* 2003; Suppl 1,52: Abstract 850250.
6. **McLaughlin T**, Carter S, Abbasi F, Lamendola C, Chu J, Basina M, Tuan C, Reaven G. Weight loss in obese individuals: 40% versus 60% carbohydrate diet. *Diabetes* 2003; Suppl 1,52:A73, Abstract 312-OR.
7. **McLaughlin T**, Abbasi F, Lamendola C, Reaven GM. Use of plasma triglyceride to high density lipoprotein cholesterol ratio to identify insulin resistant individuals at risk for cardiovascular disease and diabetes. *Diabetes* 2003; Suppl 1,52:A224, Abstract 962-P.
8. **McLaughlin T**, Reaven GM, Lamendola C, Abbasi F, Tsao P. Asymmetric dimethylarginine is elevated in obese, insulin-resistant women and decreases with weight loss. *Atherosclerosis, Thrombosis, and Vascular Biology* 5th Annual Conference, San Francisco, CA, 2004. Abstract ATVB-A-21-AHA.
9. **McLaughlin T**, Abbasi F, Wolfert R, Lamendola C, Reaven G, Reaven P. Lipoprotein-associated phospholipase (LpPLA2) is not increased in association with insulin resistance. *Atherosclerosis, Thrombosis, and Vascular Biology* 5th Annual Conference, San Francisco, CA, 2004. Abstract ATVB-A-310-AHA.
10. **McLaughlin T**, Abbasi F, Lamendola C, Carter S, Reaven G. Weight loss in insulin resistant obese individuals: 60% vs 40% carbohydrate diet. *J Investigative Medicine* 2004; 52 (2):S385, Abstract 47.

11. **McLaughlin T**, Sherman A, Yee G, Lamendola C, Gonzalez, O, Tsao P, Reaven G, Cushman S. Evidence of impaired adipocyte differentiation in obese insulin-resistant individuals. *Diabetes* 2005, Suppl 52.
12. Liu, Teresa, Morton, J, Abbasi F, Lamendola C, Yee G, Reaven G, **McLaughlin T**. Insulin resistant overweight and moderately obese have a similar risk profile to morbidly obese nondiabetic adults. *Diabetes and Vascular Disease Research* 2007; 4(3): 265.
13. Liu A, Yee G, Lamendola C, Morton J, Cushman S, Reaven GM, Tsao P, **McLaughlin T**. Association of insulin resistance with differential gene expression in subcutaneous and visceral adipose tissue of gastric bypass patients. *Diabetes and Vascular Disease Research* 2007; 4(3): 264.
14. Gonzalez O, Yee G, Deng A, **McLaughlin T**, Tsao P. Inflammation is not associated with insulin resistance in equally obese subjects. *Diabetes and Vascular Disease Research* 2007; 4(3): 262.
15. Gonzalez O, Yee G, Deng A, Reaven G, Tsao P, Tomlinson P, **McLaughlin T**. Dysregulation of Cortisol Metabolism is Associated with Insulin Resistance Independent of BMI. *Diabetes* 2009, Suppl 52.
16. Kim SH, Liu T, Abbasi F, Lamendola C, Morton JM, Reaven GM, **McLaughlin T**. Plasma Glucose and Insulin Regulation is Abnormal Following Gastric Bypass Surgery with or without Neuroglycopenia. *Diabetes* 2009, Suppl 52.
17. **McLaughlin T**, Peck M, Deacon C. Post-Gastric Bypass Hyperinsulinemic Hypoglycemia: Reversal with Percutaneous Endoscopic Gastrostomy P1-438. Endocrine Society Annual Meeting Poster Presentation, 2009.
18. Coghlan N, Lamendola C, Carter S, Abbasi F, Reaven G, **McLaughlin T**. Effects of a low carbohydrate diet on insulin resistance in obese subjects with PCOS. Abstract from the 7th Annual World congress on Insulin Resistance. *Diabetes and Vascular Disease Research*. Jan 2010:94.
19. **McLaughlin T**, Peck M, Coghlan N, Lamendola C, Weiss D. Exenatide/Diet vs Diet Alone for Treatment of Prediabetes, P34LB. *Diabetes* 2011, Suppl 52.
20. Yue P, Abbasi FA, Deng AC, **McLaughlin TL**, Reaven GM, Tsao PS. Apelin expression in human adipocytes is associated with insulin sensitivity. *Diabetes* 2011, Suppl 52.
21. Lerner K, Liu L, Lamendola C, **McLaughlin T**. Vascular Endothelial Growth Factor (VEGF) Expression is Reduced in Adipose Tissue of Insulin-resistant Versus Insulin-sensitive Humans. Abstract from the 9th Annual World congress on Insulin Resistance. *Diabetes and Vascular Disease Research*. Jan 2012.

Not shown above: five abstracts at 2013 ENDO, San Francisco;
 three at 2014 American Diabetes Association, San Francisco; two at 2015 ENDO, San Diego;
 one at 2015 ADA Boston; two at 2016 ADA, New Orleans; multiple at genetics/other
 conferences presented by collaborators

Invited presentations (38 titles: other local talks not shown)

1. "Obesity and Insulin Resistance: A Fresh Look at an Old Problem," American Diabetes Association's 49th Annual Advanced Postgraduate Course, San Francisco, CA. February 2001.
2. "The Relationship Between Obesity and Insulin Resistance," American Association of Clinical Endocrinologists/American College of Endocrinology: Insulin Resistance Syndrome Consensus Conference, Washington D.C. August 2002.
3. "Obesity, Insulin Resistance and Cardiovascular Disease: Targeting the Highest Risk Patients," American Heart Association, Redwood City, CA. March 2003.
4. "Workshop on Obesity: Its Relationship to Insulin Resistance Syndrome." 1st Annual World Congress on the Insulin Resistance Syndrome. Las Vegas, CA. November 2003.
5. "Obesity and Insulin Resistance: the Heart of Coronary Artery Disease." American College of Cardiology, California Chapter 14th Annual Conference, Monterey, CA. December 2003.
6. "Type 2 Diabetes and Cardiovascular Disease: The Real Challenge." Health Education and Risk Reduction Training Conference, Stanford University, Stanford, CA. September 2004.
7. "Medical Aspects of Obesity." Northern California Gastrointestinal Society. Yosemite, CA. November 2004.
8. "State-of-the-Art Lecture: Obesity, Insulin Resistance, and Cardiovascular Disease." American Federation for Medical Research, Western Regional Meeting. Carmel, CA. February 2005.
9. "Weight Loss with Fat-Restricted vs Carbohydrate-Restricted Diets. Kaiser Permanente, Redwood City, CA. February, 2005.
10. "Obesity and Insulin Resistance." 3rd Annual World Congress on the Insulin Resistance Syndrome. San Francisco, CA. November 2005.
11. "Weight Loss with Fat-Restricted vs Carbohydrate-Restricted Diets. Kaiser Permanente, Santa Teresa, San Jose, CA. April, 2006
12. "Obesity and Insulin Resistance: From Bedside to Bench." 4th Annual World Congress on the Insulin Resistance Syndrome. Las Vegas, NV. October 2006.
13. "The Insulin Resistance Diet: Does it Exist?" 4th Annual World Congress on the Insulin Resistance Syndrome. Las Vegas, NV. October 2006.
14. "Obesity, Inflammation, and Cardiovascular Risk." International Stroke Conference, American Heart Association. San Francisco, CA. February 2007.
15. "A Proactive Approach to Diabetes Prevention and Management." Preventive Cardiovascular Nurses Association. Minneapolis, MN. April 2007.

16. "Obesity and Insulin Resistance: From Bedside to Bench." 5th Annual World Congress on the Insulin Resistance Syndrome. Boston, MA. October 2007.
17. "The Obese Patient: How to Identify the High-risk Patient and Intervene Early." 5th Annual World Congress on the Insulin Resistance Syndrome. Boston, MA. October 2007.
18. "Obesity and Insulin Resistance: From Bedside to Bench." Stanford Healthy Weight Seminar. Stanford, CA. June 2008.
19. Cystic Fibrosis Related Diabetes. Cystic Fibrosis Core Lecture. Stanford, CA, September 2008.
20. Type 2 Diabetes Mellitus. Stanford University Human Physiology Core Lecture. 2007-2008.
21. Obesity. Stanford University Human Physiology Core Lecture. 2007-2008.
23. "Obesity and Insulin Resistance: From Bedside to Bench." 6th Annual World Congress on the Insulin Resistance Syndrome. Los Angeles, CA. September, 2008.
24. "Diabetes Management in the Pre- and Post-Transplant Population." Center for Nursing Education. Stanford, CA. October, 2008.
25. "Polycystic Ovarian Syndrome." Vaden Health Center. January, 2009
26. "Is There a Best Diet for Weight Loss?" Endocrine Society, Annual Meeting. Washington DC. June, 2009.
27. "Importance of Subcutaneous Fat. 7th Annual World Congress on the Insulin Resistance Syndrome. San Francisco, CA. November 2009.
28. "Fat Mass and Distribution: Relationship to Insulin Resistance." 8th Annual World Congress on Insulin Resistance Syndrome. Los Angeles, CA. November 2010.
29. "Fat on Fire": Symposium Chair. Endocrine Society, Annual Meeting, San Diego CA. June 2011.
30. "Obesity and Insulin Resistance: Clinical Studies Implicating Impaired Adipocyte Differentiation." NIH/NIDDK. March 2011.
31. "Obesity and Insulin Resistance: Focus on the Fat Cell." Medicine Grand Rounds, Stanford University. March, 2011.
32. "Cystic Fibrosis-Related Diabetes." Cystic Fibrosis Foundation. Palo Alto, CA. September 2011.
33. Hyperinsulinemic Hypoglycemia Following Gastric Bypass: The Search for a Cure. Lecture for American Diabetes Association, Local Chapter. Stanford University. September 2011.
34. "Update on in-patient hyperglycemia management." Stanford CME Conference. Stanford University. October 2011.

35. "Obesity and Insulin Resistance: Focus on the Fat Cell." 9th Annual World Congress on Insulin Resistance Syndrome. Los Angeles, CA. November 2011.
36. Additional presentations **annually** at World Congress on Insulin Resistance and Endocrinology Grand Rounds at Stanford.
37. Practical Clinical Strategies to Manage the Obese Patient. Southern Diabetes Initiative. Three lectures in North Carolina, Arkansas, Tennessee, 2016.
38. Update on Cystic Fibrosis-related Diabetes. Cystic Fibrosis Grand Rounds. Stanford, CA, August 2016